Merck & Co., Inc. (NYSE:MRK)
- Dividend Yield
- 2.6%
- Consensus Rating
- Moderate Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 12 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $134.58 (17.1% Upside)
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Read More
